Mr. Steve Martin

on “The Science of Persuasion: A program for health care professionals” London, U.K.
Influence At Work (UK) Ltd
960 Capability Green
Luton LU1 3PE U.K.

Steve Martin is an expert in the field of influence and persuasion and together with world leading social psychologist Professor Robert Cialdini and Dr Noah Goldstein, is co-author of the International bestselling book Yes! 50 Secrets from the Science of Persuasion - a New York Times, Wall Street Journal and Business Week Bestseller.

Ideas and insights from the book have been recognized by the Harvard Business Review as one of their “2009 Breakthrough Ideas for Business Today”. In 2008 Yes! was nominated for the Royal Society Book Prize – the world's most prestigious prize for science writing.

Steve's popular monthly column “Persuasion” features in British Airways in flight magazine Business Life and is read by almost ¾ million people every month. He also writes a regular monthly column for the Institute of Leadership and Management.

Yes! 50 Secrets from the Science of Persuasion has featured widely in the press as well as appearing on over 30 television and radio broadcasts. The book has recently featured on a series of films produced by NBC's “Your Business” in the USA.

Steve regularly presents on the subject of influence and persuasion at a number of business schools and consults for a wide variety of commercial and government organisations including GlaxoSmithKline, Shell, AstraZeneca, Nike, Nationwide, Sears, Microsoft, Sutter Health, Bausch & Lomb, the Home Office and the Prime Minister's Strategy Unit at 10 Downing Street.

Donald M. Arnold, MD, MSc, FRCP(C)

Assistant Professor, Dept. of Medicine, McMaster University
Hematologist, Service of Clinical Hematology
MTRP Research Scientist
McMaster University, HHS Room 3V48

Dr. Arnold is an Assistant Professor in the Department of Medicine, Division of Hematology and Thromboembolism at McMaster University and Deputy Medical Director of the Ontario Provincial Platelet Immunology Laboratory. Dr. Arnold is the Director of the Transfusion Medicine Residency Program and a Research Scientist in the McMaster Transfusion Research Program. He holds a New Investigator Award from the Canadian Institutes for Health Research (CIHR).

Dr. Arnold obtained his Medical Degree from McGill University in 1997 and his Master's in Health Research Methodology from McMaster University in 2006. He completed his residency training in Internal Medicine at the Sir Mortimer B. Davis Jewish General Hospital in Montreal in 2001, Hematology at McMaster University in 2003, and Transfusion Medicine at McMaster through the Canadian Blood Services (CBS) in 2005.

Dr. Arnold's research interest is in platelet disorders with a focus on immune mediated platelet diseases such as ITP, TTP, and HIT. He has combined laboratory skills in platelet immunology with clinical skills in platelet disorders to conduct translational research in immune-mediated platelet diseases. Dr. Arnold is the Principal Investigator of a Canadian multi-centered trial of rituximab in ITP. Other research interests include the optimal use of platelet transfusions in critically ill patients and transfusion reactions.

Isabelle Bence-Bruckler MD, FRCPC

Hematologist, Division of Hematology
#7209 The Ottawa Hospital, General Campus
501 Smyth Road
Ottawa, ON K1H 8L6

Isabelle Bence-Bruckler is an Associate Professor of Medicine at the Ottawa University in Ottawa, Ontario. She is a Clinical Hematologist and member of the Bone Marrow Transplant Program at the Ottawa General Hospital. She is also the Clinical Director of the Lymphoma Program and of the Malignant Hematology Trials Group at the Ottawa General. She sits on the Scientific Advisory Board of Lymphoma Foundation Canada and is an active member of the Ontario Hematology Provincial Disease Site Group. Her clinical interests are in lymphoproliferative disorders and CML.

Christine Chen MD, FRCP(C)

Assistant Professor at The University of Toronto
hematologist at Princess Margaret Hospital,
University Health Network
5th Floor Rm 220 610 University Ave
Toronto, ON M5G 2M9

Christine Chen is an assistant professor at the University of Toronto (U of T) and hematology faculty at the Princess Margaret Hospital (PMH). She is part of an active clinical research group for multiple myeloma and related mature B-cell disorders at the PMH, including chronic lymphocytic leukemia (CLL) and Waldenstrom’s macroglobulinemia (WM).

Her clinical and research interests focus on novel approaches for CLL and WM. Dr. Chen underwent her internal medicine training at the University of British Columbia in Vancouver and hematology residency training at McMaster University in Hamilton.

Upon completing a transplant clinical research fellowship at PMH, she joined the faculty of the Department of Medical Oncology and Hematology at the U of T and subsequently obtained her Masters in Education from the Ontario Institute of Studies in Education/U of T.

She therefore takes an active role in education of both patients and trainees and acts as the education coordinator for the Myeloma Group and the Director of the Hematology Training Program at the University of Toronto.

Matthew Cheung, MD, SM, FRCP(C)

Hematology/Medical Oncology
Sunnybrook Health Sciences Centre
2075 Bayview Ave. T2-031
Toronto ON M4N 3M5

Dr. Cheung obtained his Medical Degree in 1999 at the University of Toronto. He completed residency programs in Internal Medicine and Hematology from 1999-2004 at the University of Toronto. Thereafter, he completed a clinical and research fellowship in Lymphoma and a Canadian Institutes of Health Research (CIHR) HIV/AIDS post-doctoral research fellowship. In 2006, he obtained a Masters degree in Clinical Epidemiology at the Harvard School of Public Health in Boston. He currently holds peer-reviewed grant support from CIHR, the National Cancer Institute of Canada, and the Canadian Foundation for AIDS Research (CANFAR).

Dr. Cheung joined the medical staff at the Odette Cancer Centre/Sunnybrook Health Sciences Centre as a Clinician-Investigator and Clinical Hematologist in 2007. He is currently an Assistant Professor in the Department of Medicine at the University of Toronto. He serves on the Hematology Disease Site Executive Committee for the National Cancer Institute of Canada Clinical Trials Group and is a member of the Hematology Cancer Disease Site Group of the Cancer Care Ontario Program in Evidence-Based Care. His research interests include AIDS-related malignancies, clinical trial development in lymphoma, and pharmacoeconomic evaluation in the hematologic malignancies.

Ian Chin-Yee MD, FRCP(C)

Chief/Chair of the Division of Hematology, Department of Medicine,
University of Western Ontario
London Health Sciences Centre
800 Commissioners Rd. East
London, ON N6A 4G5

Dr. Ian Chin-Yee is Chief/Chair of the Division of Hematology, Department of Medicine, at the University of Western Ontario, Consultant in the Department of Medicine at the London Health Sciences Centre as well as Professor of Medicine at the University of Western Ontario. He also holds a Cross Appointment as an Honourary Consultant in Hematology/Oncology at the London Regional Cancer Centre. He is also an Associate Medical Director/Consultant of the Canadian Blood Services, London Centre. Recently he has been appointed the Medical Director, Adults, Bleeding Disorders Program, LHSC.

Dr. Chin-Yee obtained his Medical Degree at the University of Calgary and did his residency training in Internal Medicine/Hematology at the University of Western Ontario.

His research interests lay in the fields of stem cells, and transfusion medicine performed in collaboration with the AC Burton Vascular Lab in London and Robarts Research Institute and Lawson Health Research Institute.

“Our interest in Hematopoietic stem cells has focused on improving quality of the stem cell product and novel mobilization methods for peripheral blood stem cells. Efforts in the area of quality assurance stem cell enumeration led to development of a proficiency program of numerous centers in Ontario and throughout Canada. This involvement has led to the international recognition of the methodology developed in part in our lab for enumeration of stem cells.” Recent co-recipient of CFI grant to develop START Program, (Stem Cell Transplantation and Regenerative Therapeutics) a regional integration of clinical, technologies and basic research program aimed at developing stem cell based regenerative therapies for cardiac and pancreatic tissue.

Research in the area of transfusion medicine has focused on the effects of storage on RBC oxygen delivery and evaluation of hemoglobin based on oxygen carriers. Current research funding in this area from Canadian Blood Services for Grant entitled – “Does Prestorage Leukoreduction Reduce Red Cell Adhesion and Improve Tissue Oxygenation in Microvasculature.” Current research funding has been obtained for studies into the effects of prestorage leukoreduction on RBC adhesion and oxygen delivery in vivo in an animal model.

Joseph Connors MD, FRCPC

Chair, BCCA Lymphoma Tumor Group
Clinical Director, BCCA Centre for Lymphoid Cancer,
600 West 10th Ave,
Vancouver, BC V5Z 4E6

Joseph M. Connors, MD is a clinical professor in the Department of Medicine, Division of Medical Oncology, at the University of British Columbia and the chair of the Lymphoma Tumor Group for the British Columbia Cancer Agency.

Dr. Connors obtained his medical degree at Yale University, trained in internal medicine at the University of North Carolina in Chapel Hill, and completed his medical oncology fellowship with Dr. Saul Rosenberg at the Stanford University Medical Center from 1979 to 1981. He then joined the staff and faculty at the BC Cancer Agency and University of British Columbia and has focused his clinical activities and research efforts in the area of understanding lymphoid cancers.

Dr. Connors is best known for his clinical investigations into the treatment of Hodgkin lymphoma, non-Hodgkin lymphoma, chronic lymphocytic leukemias and multiple myeloma. He serves as a member of the executive committee of the Hematology Site Group for the National Cancer Institute of Canada Clinical Trials Group, as chair of the small meetings subcommittee of the Education Committee of the American Society of Hematology and on the scientific advisory boards of the Lymphoma Foundation Canada and the Lymphoma Research Foundation of the United States.

Dr. Connors has published over 180 peer-reviewed scientific articles addressing various aspects of research into lymphoid cancers. He has been awarded the Terry Fox Cancer Research Award by the British Columbia Medical Association, the Bernard L. Schwartz Memorial Award by the Scripps health system in San Diego, California, and the Canadian Cancer Society John W. Whittick Memorial Award by the Saskatchewan Medical Association.

R. Michael Crump FRCPC, MD

Department of Medical Oncology and Hematology
Princess Margaret Hospital
Toronto, Ontario

Dr. Michael Crump graduated from the University of Toronto and completed training in internal medicine, hematology and medical oncology in Toronto, and bone marrow transplantation at Duke University. His research interests have included stem cell transplantation in lymphoma and solid tumors, and more recently, novel therapies in hematologic malignancies, in particular in lymphoma. He is Co-Chair of the Hematology Site Group and Chair of the Lymphoma Working Group of the National Cancer Institute of Canada Clinical Trials Group; and Lymphoma Site leader and Director of the Autologous Stem Cell Transplant Service at Princess Margaret Hospital in Toronto.

Barbara Eichhorst MD

The German CLL Study Group (GCLLSG),
Department for Internal Medicine,
University Hospital of Cologne, Germany
Kerpener Str. 62, 50937 Cologne
Germany

Barbara Eichhorst graduated at the Medical school of the University of Munich in 1997. She did her doctoral thesis in the field of hemataology evaluating signalling transduction pathways in Hodgkin cells. Dr Eichhorst finished her internship at the department III for Internal medicine at Klinikum Großhadern of the University of Munich becoming consultant for internal medicine. Since February 2005 she works at the University hospital of Cologne and is a consultant in hematology and internal oncology since April 2006.

Shortly after the foundation of the German CLL Study Group (GCLLSG) she became a member of the leading group of the GCLLSG acting as principal investigator in several phase II and III trials evaluating treatment optimization in CLL. Since 2005 she is secretary of the GCLLSG, which is conducted by Prof. Michael Hallek. Publishing several papers on the topic of treatment of CLL within clinical trials Barbara Eichhorst is a world-wide known specialist in the field of CLL.

Carolyn Hamm MD FRCPC

Medical Oncologist,
Director of Research,
Director of Clinical Trials,
Windsor Regional Cancer Centre
2220 Kildare Road
Windsor ON N8W 2X3

Dr. Hamm grew up in Kingsville & graduated from Dalhousie Medical School in Nova Scotia. She trained in internal medicine and oncology in Ottawa and specialized in the area of bone marrow transplantation at Karmanos Cancer Institute in Detroit. She has been with the Windsor Regional Hospital since July 2002 and her areas of focus are breast cancer, leukemias, lymphomas and melanoma. She is also the Chair of Clinical Trials and Research.

C. Tom Kouroukis MD MSc. FRCPC

Assistant Professor, McMaster University
Department of Oncology - Division of Malignant Hematology
Juravinski Cancer Centre
3rd Floor
699 Concession Street
Hamilton, ON L8V 5C2

Dr. C. Tom Kouroukis completed his MD degree with Honours from the University of Toronto in 1993 and subsequently pursued training in Internal Medicine at McGill University and Hematology training at McMaster University. He was awarded a National Cancer Institute of Canada Clinical Research Fellowship and was a Clinical Scholar at McMaster University from 1998 to 2001. He obtained his Masters in Science in Health Research Methodology at McMaster under the supervision of Dr. George Browman. He is currently a Staff Hematologist at the Juravinski Cancer Centre/Hamilton Health Sciences, Head of the Hematology Program at the Juravinski Cancer Centre, Head of the Hematology Service at Hamilton Health Sciences and Associate Professor in the Department of Oncology, McMaster University. He is Co-Chair of the Hematology Cancer Disease Site group of the Cancer Care Ontario Practice Guidelines Initiative. His clinical practice involves the care of patients with a variety of hematological malignancies. He is the Canadian Representative to the International Society of Geriatric Oncology. His research interests centre around the care of older patients with hematological cancers, the impact and evaluation of comorbidity in older cancer patients, clinical trials in mantle cell lymphoma and practice guideline development.

John Kuruvilla MD, FRCP(C)

Hematology/Medical Oncology
University Health Network
Princess Margaret Hospital
Room 5-110
610 University Avenue
Toronto, ON M5G 2M9

Dr. John Kuruvilla went to medical school at the University of Toronto and subsequently completed his residency in Internal Medicine at the University of Western Ontario in London. He moved to Vancouver where he completed subspecialty training in hematology. It was there while working with the Leukemia/Bone Marrow Transplant Program of British Columbia and the Lymphoma tumour group at the British Columbia Cancer Agency that he developed his interest in lymphoma and blood and marrow transplantation. Next, he completed a fellowship at Princess Margaret Hospital in Toronto with a focus in lymphoma and blood and marrow transplantation. Currently he is a staff physician with the Lymphoma Tumour Group at Princess Margaret Hospital as well as a member of the Blood and Marrow Transplant Program.

His interests include drug development in lymphoma, clinical trials in lymphoma and transplantation and pharmacoeconomics.

Brent Zanke MD FRCPC

Scientist/Oncologist The Ottawa Hospital,
Associate Professor of Medicine
University of Ottawa

Brent Zanke graduate of the Universities of Manitoba (MD, 1983) and Toronto (PhD, 1993) and a Fellow of the Royal College of Physicians of Canada with speciality certification in internal medicine and medical oncology. He conducted basic and translational laboratory-based research at the Ontario Cancer Institute before assuming administrative duties as Director of the Cross Cancer Institute in Edmonton, one of Canada’s two free standing cancer hospitals. He was the Provincial Head of Systemic Therapy for Cancer Care Ontario from 2002 until 2006.

Dr. Zanke also leads the multi-site Ontario tumor bioprofiling initiative of the Ontario Cancer Research Network (www.ontariotumorbank.ca). This large scale project is part of an ongoing bio-informatics effort to organise clinical outcome measures with biologic profiles of human tumors. He also conducts large scale biomarker and genetic predictors of colon cancer risk having received funding from Genome Canada, the Canadian Cancer Society and the Ontario Ministry of Research and Innovation. He is founder and Chairman of ArcticDx, a Canadian private molecular diagnostics company where he also fills the role of Chief Medical Officer.